Immunotherapy News and Research

Latest Immunotherapy News and Research

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.

7 Nov 2014

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

The Multiple Myeloma Research Foundation today announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM).

6 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy.

3 Nov 2014

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML).

30 Oct 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown.

21 Oct 2014

Van Andel Research Institute commits $7.5M to support epigenetic therapy in cancer treatment

The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI).

20 Oct 2014

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer.

16 Oct 2014

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.

16 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

BCRF announces $58.6 million commitment to breast cancer research

The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.

10 Oct 2014

CytoSorbents named Health sector winner at 2014 GREAT Tech Awards Gala

CytoSorbents Corporation is proud to announce that it was named the Health sector winner at the 2014 GREAT Tech Awards Gala last evening. Sponsored by United Kingdom Trade & Investment and the British Consulate General New York, the GREAT Tech Awards selected one winner in each of six categories from a pool of 120 high growth companies from New York, New Jersey, Pennsylvania and Connecticut.

10 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.

8 Oct 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

TxCell to highlight development, progress of ASTrIA platform at 13th Annual BIO Investor Forum

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.

3 Oct 2014

CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.

3 Oct 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Study suggests possible link between body fat and risk of immunotherapy toxicity

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

UC Davis researchers link increased body fat and lethal drug reactions in mice

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

Crown Bioscience announces U.S. expansion with new translational oncology center

Van Andel Research Institute commits $7.5M to support epigenetic therapy in cancer treatment

Researchers identify novel method to develop personalized vaccines for ovarian cancer

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

BCRF announces $58.6 million commitment to breast cancer research

CytoSorbents named Health sector winner at 2014 GREAT Tech Awards Gala

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

TxCell to highlight development, progress of ASTrIA platform at 13th Annual BIO Investor Forum

CytoSorbents announces launch of International CytoSorb Treatment Registry

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in